LEADER 01419nas 2200505-a 450 001 996199474903316 005 20240112213020.0 011 $a1472-6831 035 $a(DE-599)ZDB2091511-1 035 $a(OCoLC)48983838 035 $a(CKB)111032787578020 035 $a(CONSER)--2002243113 035 $a(EXLCZ)99111032787578020 100 $a20020212a20019999 s-- a 101 0 $aeng 135 $aurcn||||||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aBMC oral health 210 $aLondon $cBioMed Central$d2001- 300 $aRefereed/Peer-reviewed 300 $aTitle from BioMed Central archive volume screen (viewed Feb. 20, 2002). 517 3 $aBioMed Central oral health 517 3 $aOral health 531 $aBMC ORAL HEALTH 531 10$aBMC Oral Health 606 $aOral medicine$vPeriodicals 606 $aMouth Diseases 606 $aTooth Diseases 606 $aOral medicine$2fast$3(OCoLC)fst01047088 608 $aPeriodical. 608 $aFulltext. 608 $aInternet Resources. 608 $aPeriodicals. 608 $aPeriodicals.$2fast 610 $aDentistry - General 615 0$aOral medicine 615 12$aMouth Diseases. 615 22$aTooth Diseases. 615 7$aOral medicine. 906 $aJOURNAL 912 $a996199474903316 996 $aBMC oral health$92065198 997 $aUNISA LEADER 03139nam 2200361z- 450 001 9910136403703321 005 20210211 035 $a(CKB)3710000000612060 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/54550 035 $a(oapen)doab54550 035 $a(EXLCZ)993710000000612060 100 $a20202102d2014 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aNew anti-infective strategies for treatment of tularemia 210 $cFrontiers Media SA$d2014 215 $a1 online resource (78 p.) 225 1 $aFrontiers Research Topics 311 08$a2-88919-339-X 330 $aFrancisella tularensis, the causative agent of tularemia, is a paradigm among human pathogens. This Gram-negative bacterium has an intracellular lifestyle, which probably reflects an adaptation to its natural animal and protozoa reservoirs. This is one of the most infectious agents in humans and animals; only a few bacteria are needed to induce a severe infection in both types of hosts. The clinical presentation and severity of human tularemia varies according to the portal of entry of bacteria, the bacterial inoculum, the virulence of the infecting strain, and the immune response of the host. Although most infections occur after direct inoculation of bacteria through the skin (through skin wounds or bites of arthropods), pneumonia due to inhalation of infected aerosols is the most feared of the clinical forms of the disease, particularly in the context of biological threat. Two subspecies are responsible for tularemia (subsp. tularensis and subsp. holarctica), and several clades have been described for each, which might be associated with changes in disease severity in humans. Tularemia is also more severe in people with an impaired immune response. No safe vaccine is currently available for prophylaxis of tularemia in humans. On the other hand, control of proliferation of F. tularensis in wildlife is not feasible. Thus, only the anti-infective agents are used for treatment and prophylaxis of human tularemia. The standard options include aminoglycosides (gentamicin), tetracyclines (eg, doxycycline) and fluoroquinolones (eg, ciprofloxacin). The selection of acquired resistance to these antibiotics in F. tularensis, especially in the context of a biological threat, may quickly limit the therapeutic options. New prophylactic and therapeutic alternatives must be developed rapidly. The present Research Topic focuses on potential new strategies for treatment of tularemia, including the development and evaluation of new compounds having proper antibacterial activity, reducing the virulence of F. tularensis or enhancing the immune host response. 610 $aantiinfective agents 610 $aFrancisella tularensis 610 $aimmunomodulators 610 $aTularemia 610 $aVirulence 700 $aMax Maurin$4auth$01287805 906 $aBOOK 912 $a9910136403703321 996 $aNew anti-infective strategies for treatment of tularemia$93020428 997 $aUNINA